Presentations at OIS Retina 2024:
- Session Title: “Spotlight on Drug Delivery”
Session Date/Time:Saturday, May 4th ,11:15 AM –12:00 PM PDT
Ocular Presentation: 11:34 –11:41 AM PDT
Presenter:Sanjay Nayak , MBBS, PhD, Chief Strategy Officer
- Panel Title: “The View from the Street”
Session Date/Time:Saturday, May 4th at 5:00 –5:30 PM PDT
Moderator: Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer
Presentations at ARVO 2024:
- Oral Presentation: Pharmacodynamic efficacy of second-generation intravitreal axitinib implant (AXPAXLI) in a VEGF challenge rabbit model
Session Date/Time:Thursday, May 9th 3:30 –3:45 PM PDT
Location:Yakima 1 -Seattle Convention Center -Arch Building
Presenter:Chuck Blizzard , Vice President, Research & Development
- Poster Title: Long-term safety of repeated intravitreal axitinib implant (AXPAXLI) administrations in non-human primates
Poster Board #: B0299
Session Date/Time:Monday, May 6th 8:30 –10:15 AM PDT
Location: Exhibit Hall –Seattle Convention Center
Presenter:Chintan Patel , PhD, Associate Director,Nonclinical Development
- Poster Title: Optimized pharmacokinetic profile of intravitreal axitinib implant (AXPAXLI):
a comparison of first- and second-generation implants
Poster Board #: B0300
Session Date/Time:Monday, May 6th 8:30 –10:15 AM PDT
Location: Exhibit Hall –Seattle Convention Center
Presenter: Madhoosudan Patil, PhD, Senior Scientist
About Ocular Therapeutix, Inc.
Ocular’s expertise in the formulation, development and commercialization of innovative therapies of the eye and the ELUTYX platform supported the development and launch of its first commercial drug product, DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. ELUTYX is also the foundation for two other clinical-stage assets, OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, as well as several preclinical programs.
Follow us on our website, LinkedIn or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, and ELUTYX™ and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
About DEXTENZA
DEXTENZA is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the inner portion of the lower eyelid, and into the canaliculus, and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. DEXTENZA resorbs and exits the nasolacrimal system without the need for removal.
Please see full Prescribing and Safety Information at the DEXTENZA website.
Forward-Looking Statements
Any statements in this press release about future expectations, plans, and prospects for the Company, including the development and regulatory status of the Company’s product candidates, including the timing, design, and enrollment of the Company’s Phase 3 trials of AXPAXLI (also called OTX-TKI) for the treatment of wet AMD and the Company’s planned Phase 3 clinical development program of AXPAXLI for the treatment of diabetic retinopathy; the Company’s plans to advance the development of AXPAXLI, PAXTRAVA and its other product candidates; the potential utility of any of the Company’s product candidates; the sufficiency of the Company’s cash resources; and other statements containing the words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “goal”, “may”, “might”, “plan”, “predict”, “project”, “target”, “potential”, “will”, “would”, “could”, “should”, “continue”, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and costs involved in commercializing DEXTENZA or any product or product candidate that receives regulatory approval; the ability to retain regulatory approval of DEXTENZA or any product or product candidate that receives regulatory approval; the initiation, design, timing, conduct and outcomes of clinical trials, including the
Investors & Media
Vice President, Investor Relations
bslattery@ocutx.com
Source:
2024 GlobeNewswire, Inc., source